Medical Advocates

HIV Infection/Disease
  Lipoatrophy
 
 
General Reports
Facial Lipoatrophy
Diagnostics/Monitoring
Clinical Management
Mitochondrial Disorders





 


 

HIV Metabolic Main Page   Main New/Newsworthy Home Page  

Last Update: September 06, 2016
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports

       

          Journal Papers, Abstracts, and Commentaries
 
 

FULL-TEXT PDF ARTICLE
High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study.
I
nnes S, Cotton MF, Haubrich R, W, Hough S, Browne SH.
BMC Pediat
r
. 2012 Nov 23;12(1):183.
Paper

FULL-TEXT PDF ARTICLE
Economic Modeling of the Combined Effects of HIV-Disease, Cholesterol and Lipoatrophy Based on ACTG 5142 Trial Data
Simpson KN, Dietz B, Baran R,
Cost Effectiveness and Resource Allocation 2011, 9:5
Paper

Human Immunodeficiency Virus Treatment-Induced Adipose Tissue Pathology and Lipoatrophy: Prevalence and Metabolic Consequences.
Hammond E, McKinnon E, Nolan D.
Clin Infect Dis. 2010 Jul 20.
Abstract

Lipoatrophy of the Footpad in HIV-Treated Patients Is Associated With Increased PAI-1.
Eriksson LE, Schonnesson LN, Bratt GA.

Biol Res Nurs
. 2009 Nov 25.
Abstract

Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort.
Brown TT, Smurzynski M, Wu K, et al
Antivir Ther. 2009;14(6):853-8
Abstract

How Much Fat Loss Is Needed for Lipoatrophy to Become Clinically Evident?
Podzamczer D, Ferrer E, Martínez E, et al

AIDS Res Hum Retroviruses
. 2009 Jun 5
Abstract

Cost consequences of HIV-associated lipoatrophy.
Hornberger J, Rajagopalan R, Shewade A, Loutfy MR.

AIDS Care
. 2009 May;21(5):664-71.
Abstract

Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.
McComsey GA, Libutti DE, O'Riordan M, et al

Antivir Ther.
2008;13(5):715-22.
Abstract

Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.
Doward LC, Dietz B, Wilburn J,  

AIDS Read.
2008 May;18(5):242-6, 252-6,
Abstract
 

Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipoatrophy during antiretroviral therapy: a case-control study.
Wunder DM, Fux CA, Bersinger NA, et al
HIV Med. 2008 May 3
Abstract
 
Association of APOC3 Polymorphisms with Both Dyslipidemia and Lipoatrophy in HAART-Receiving Patients.
Bonnet E, Bernard J, Fauvel J, Massip P
AIDS Res Hum Retroviruses. 2008 Feb 1
Abstract
 
Antiretroviral Therapies Associated with Lipoatrophy in HIV-Infected Women.
Tien PC, Barron Y, Justman JE, et al
AIDS Patient Care STDS. 2007 May;21(5):297-305
Abstract
 
Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Hansen A, Lindegaard B, Obel N, et al
HIV Med.
2006 Jan;7(1):38-45
Abstract
 
FULL-TEXT ARTICLE
Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for
HIV1 infection: case report.
Parruti G, Marani Toro G.
BMC Infect Dis. 2005 Oct 3;5(1):80
Paper
 
The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy.
Shah M, Tierney K, Adams-Huet B, et al
HIV Med. 2005 Jul;6(4):291-8.
Abstract
 
Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
Bergersen B, Sandvik L, Ellingsen I, Bruun J.

HIV Med. 2005 Jul;6(4):260-7.
Abstract
 
Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
McComsey G, Maa JF.
AIDS Read. 2003 Nov;13(11):539-42, 559.
Abstract

Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin.
Nagy GS, Tsiodras S, Martin LD, et al.

Clin Infect Dis
2003 Mar 15;36(6):795-802
Abstract

Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients.
Lichtenstein KA, Delaney KM, Armon C, et al.
J Acquir Immune Defic Syndr 2003 Jan 1;32(1):48-56
Abstract
 

 
              Conference Reports, Abstracts, and Posters
 
 
Low serum adiponectin level is associated with lipoatrophy among HIV-positive men in the SUN study
B. Klos, P. Patel, J. Hammer
(XIX
International AIDS Conference)
Abstract
 

Diagnostics/Monitoring

       

          Journal Papers, Abstracts, and Commentaries
 
 

Magnetic resonance imaging evaluation of lipodystrophy in HIV-positive patients receiving highly active antiretroviral therapy.
Eichler K, Bickel T, Klauke S,  et al
Int
J STD AIDS
. 2014 Aug 18.
Abstract

Accuracy of Ultrasound Imaging Technique for Assessing Lipoatrophy in HIV-Infected Subjects.
Ferraioli G, Tinelli C, Scudeller L,  et al

Curr HIV Res
. 2011 Aug 9.
Abstract

Assessment of Ultrasound for Use in Detecting Lipoatrophy in HIV-Infected Patients Taking Combination Antiretroviral Therapy.
Viskovic K, Richman I, Klasnic K, et al 
AIDS Patient Care STDS. 2009 Jan 9.

Abstract


Clinical Management

       

          Journal Papers, Abstracts, and Commentaries
 
 
Treatment of HIV-Infected Subjects with Buttock Lipoatrophy Using Stabilized Hyaluronic Acid Gel.
Claude O, Bosc R, Pigneur F, Lantieri L

Plast Reconstr Surg Glob Open
. 2015 Aug 10;3(7):e466.

Abstract

Effects of switching to PI monotherapy on measures of lipoatrophy: meta-analysis of six randomized HIV clinical trials.
Arribas J, Bernardino J, Hill A,  et al
J Int AIDS Soc. 2012 Nov 11;15(6):18281
Abstract

Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner.
Mencarelli A, Francisci D, Renga B,  et al
Antivir Ther
. 2012 Jan 25.

Abstract

Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229.
McComsey GA, Walker UA, Budhathoki CB,
et al
AIDS
. 2010 Sep 7
Abstract

Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy:
results of ACTG A5110.
Tebas P, Zhang J, Hafner R, Tashima K, et al
J Antimicrob Chemother. 2009 Mar 19.
Abstract
 

Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
Phillips DR, Hay P.  

J Antimicrob Chemother.
2008 Aug 13.
Abstract
 
A Randomized, Placebo-Controlled Trial of Rosiglitazone for HIV-Related Lipoatrophy.
Cavalcanti RB, Raboud J, Shen S, et al
J Infect Dis. 2007 Jun 15;195(12):1754-61.
Abstract

Plastic Surgical Approaches for HIV-associated Lipoatrophy.
Moyle GJ. 
Curr HIV/AIDS Rep. 2005 Aug;2(3):127-31.
Abstract

Therapeutic approaches to combating lipoatrophy: do they work?
Martin A, Mallon PW. 
J Antimicrob Chemother. 2005 Mar 10;
Abstract
 
Interventions for managing antiretroviral therapy-associated lipoatrophy.
Sutinen J. 
Curr Opin Infect Dis. 2005 Feb;18(1):25-33.
Abstract
 
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
McComsey GA, Ward DJ, Hessenthaler SM, et al.  
Clin Infect Dis. 2004 Jan 15;38(2):263-70
Abstract
 
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.
Mallon PW, Miller J, Cooper DA, Carr A.
AIDS 2003 May 2;17(7):971-9
Abstract
 
Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus -infected patients with lipoatrophy.
Estrada V, De Villar NG, Larrad MT
Clin Infect Di
s 2002 Jul 1;35(1):69-76
Abstract

Mitochondrial Disorders

       

          Journal Papers, Abstracts, and Commentaries
 
 

Mitochondrial Abnormalities in HIV-Infected Lipoatrophic Patients Treated With
Antiretroviral Agents.
Chapplain JM, Beillot J, Begue JM, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1477-1488.

Abstract
 


HIV Metabolic Main Page   Main New/Newsworthy Home Page  

Lipoatrophy